Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque

J Neuropsychiatry Clin Neurosci. Winter 1999;11(1):79-85. doi: 10.1176/jnp.11.1.79.

Abstract

The cholinesterase inhibitor tacrine (THA) and the M1 muscarinic agonist AF102B (cevimeline), both reported to enhance cognition in animals and humans, were tested in 5 macaques for reduction of spontaneous, random movements. Monkeys were videotaped 1 hour after administration of normal saline vehicle, after low- and high-dose intramuscular AF102B, and after low- and high-dose oral THA. Two independent blind judges counted numbers of spontaneous movements made by each monkey over 12 consecutive 15-second segments for each drug condition. Both THA and AF102B reduced movement significantly at high doses without overt side effects, warranting further research on the agitation-reducing potential of cognition-enhancing cholinomimetic drugs.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Animals
  • Cholinesterase Inhibitors / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Macaca radiata
  • Male
  • Motor Activity / drug effects
  • Muscarinic Agonists / therapeutic use*
  • Pilot Projects
  • Psychomotor Agitation / drug therapy*
  • Quinuclidines / therapeutic use*
  • Tacrine / therapeutic use*
  • Thiophenes*

Substances

  • Cholinesterase Inhibitors
  • Muscarinic Agonists
  • Quinuclidines
  • Thiophenes
  • Tacrine
  • cevimeline